Related Experiment Videos

Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy

J M Mefferd1, S S Donaldson, M P Link

  • 1Stanford University Medical Center, Stanford, CA 94305.

Insights

Pediatric Hodgkin

Area of Science:

  • Pediatric Oncology
  • Pulmonary Medicine
  • Cardiology
  • Endocrinology

Background:

  • Hodgkin's disease in children is curable, necessitating a focus on minimizing long-term treatment side effects.
  • Combined modality therapy (chemotherapy and radiotherapy) is standard for pediatric Hodgkin's disease.
  • Understanding the sequelae of treatment is crucial for improving long-term outcomes in survivors.

Purpose of the Study:

  • To assess post-treatment pulmonary, cardiac, and thyroid function in pediatric Hodgkin's disease survivors.
  • To identify the prevalence and nature of functional abnormalities following combined modality therapy.
  • To evaluate the impact of specific treatment components, like bleomycin and radiotherapy, on organ function.

Main Methods:

  • Retrospective analysis of 34 children (ages 5-17) treated for Hodgkin's disease.
  • Pulmonary function tests (DLCO, FEV1, FVC, TLC) performed on asymptomatic patients.
  • Cardiac nuclear gated angiograms and thyroid function tests (TSH, T4) conducted post-treatment.

Main Results:

  • Pulmonary dysfunction was substantial: 55% had abnormal diffusing capacity (DLCO), and 40% showed restrictive or obstructive abnormalities.
  • Cardiac effects were minimal, with 14% of tested patients exhibiting abnormal nuclear gated angiograms.
  • Thyroid abnormalities (elevated TSH) were observed in 21% of evaluated patients, suggesting subclinical hypothyroidism.

Conclusions:

  • Post-treatment pulmonary dysfunction is frequent and significant in asymptomatic pediatric Hodgkin's disease survivors, even after low-dose radiotherapy and limited bleomycin exposure.
  • While cardiac and thyroid sequelae appear less common, they warrant continued monitoring.
  • The long-term pulmonary effects of combined ABVD chemotherapy and radiotherapy remain largely unknown and require further investigation.

Related Concept Videos